Mobilizing hiv-infected cells from lymphatic reservoirs
AssigneesIndiana University Research and Technology Corporation, The United States of America As Represented by the Department of Veterans Affairs Office of General
InventorsMatthias Alexander Clauss, Bernhard Fidelis Maier
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating HIV infection, including retention of HIV+ T cells in viral reservoirs such as lymph nodes. More particularly, provided herein are methods in which an effective amount of a HIV Nef pathway inhibitor (e.g., anti-Nef agent) is administered to a subject in need thereof, whereby administration of the inhibitor treats HIV infection in the subject, decreases retention of HIV+ T cells in lymph nodes, and increases migration of HIV+ T cells from lymph nodes.
Claims20
A method of treating a HIV infection, the method comprising:
- administering a therapeutically effective dose of an anti-Nef agent to a patient in need thereof;
- wherein the anti-Nef agent specifically targets Nef or Nef-mediated signaling, and wherein administering the therapeutic anti-Nef agent treats the HIV infection.
(canceled)
A method for improving CD4+ T cell mediated immunity of a HIV positive patient comprising administering to the patient a therapeutically effective amount of a therapeutic anti-Nef agent, wherein said therapeutic anti-Nef agent improves CD4+ T cell mediated immunity.
A method of treating a HIV infection, the method comprising:
- administering a therapeutically effective dose of an S1P1 targeting agent able to upregulate S1P1 to a patient in need thereof;
- wherein the administering the S1P1 targeting agent treats the HIV infection.
Dependencies are inferred from the claim text.